BGM
A neo-epitope fragment of biglycan generated by MMP-9 and MMP-12 activity, reflecting pericellular matrix degradation and extracellular matrix remodeling.
Key features and values
- Serum-based assay detecting MMP-9 and MMP-12 cleaved fragments of biglycan, indicative of extracellular matrix remodeling.
- Reflects pericellular matrix degradation, providing insights into tissue remodeling dynamics.
- Validated for use in human blood samples, ensuring reliable and reproducible measurements.
- Non-invasive tool for assessing extracellular matrix remodeling, suitable for routine blood sampling.
- Elevated BGM levels correlate with increased extracellular matrix remodeling in conditions such as rheumatoid arthritis and liver fibrosis.
- Useful for monitoring therapeutic response, with changes in BGM levels reflecting the efficacy of treatments targeting extracellular matrix remodeling.
- Facilitates research and development of targeted therapies by providing insights into extracellular matrix remodeling mechanisms
Description
The BGM biomarker assay is designed to quantify matrix metalloproteinase (MMP)-9 and MMP-12 cleaved fragments of biglycan in serum, serving as a specific indicator of extracellular matrix (ECM) remodeling. Biglycan is a proteoglycan involved in collagen fibril assembly, and its cleavage by MMPs releases fragments into the bloodstream. By measuring these fragments, the assay provides a direct assessment of pathological ECM remodeling.
This assay has been validated for use in human blood samples, demonstrating its reliability and reproducibility in various clinical and research settings. Elevated serum BGM levels have been associated with increased ECM remodeling in conditions such as rheumatoid arthritis and liver fibrosis. The non-invasive nature of the test makes it suitable for routine monitoring of tissue remodeling and the effectiveness of therapies aimed at modulating ECM dynamics.
In addition to its clinical applications, the BGM assay serves as a valuable tool in research, facilitating the study of ECM remodeling mechanisms and the development of targeted treatments aimed at modulating tissue remodeling processes.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
